Your browser is no longer supported. Please, upgrade your browser.
BNTX [NASD]
BioNTech SE
Index- P/E- EPS (ttm)-0.40 Insider Own1.18% Shs Outstand314.43M Perf Week24.07%
Market Cap34.31B Forward P/E10.17 EPS next Y14.91 Insider Trans0.00% Shs Float214.95M Perf Month42.08%
Income18.10M PEG- EPS next Q2.86 Inst Own9.90% Short Float2.22% Perf Quarter43.16%
Sales574.50M P/S59.72 EPS this Y107.10% Inst Trans-5.75% Short Ratio2.60 Perf Half Y74.46%
Book/sh5.20 P/B29.14 EPS next Y-45.51% ROA1.10% Target Price125.79 Perf Year290.67%
Cash/sh7.09 P/C21.37 EPS next 5Y- ROE1.80% 52W Range37.00 - 140.79 Perf YTD85.89%
Dividend- P/FCF- EPS past 5Y- ROI4.90% 52W High7.64% Beta-
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin87.70% 52W Low309.57% ATR6.43
Employees1941 Current Ratio2.80 Sales Q/Q218.00% Oper. Margin-17.10% RSI (14)81.11 Volatility5.66% 5.02%
OptionableYes Debt/Eq0.17 EPS Q/Q237.30% Profit Margin3.20% Rel Volume2.52 Prev Close140.72
ShortableYes LT Debt/Eq0.17 EarningsMar 30 BMO Payout- Avg Volume1.83M Price151.54
Recom2.20 SMA2035.69% SMA5037.41% SMA20062.60% Volume4,620,755 Change7.69%
Dec-01-20Downgrade BofA Securities Buy → Neutral $123 → $126
Aug-03-20Resumed Berenberg Buy $98
Jul-21-20Upgrade BofA Securities Neutral → Buy $71 → $105
Jun-30-20Downgrade H.C. Wainwright Buy → Neutral
May-19-20Upgrade H.C. Wainwright Neutral → Buy $48 → $69
Apr-28-20Downgrade BofA/Merrill Buy → Neutral $46 → $51
Mar-18-20Downgrade JP Morgan Overweight → Neutral $23 → $33
Mar-09-20Initiated H.C. Wainwright Neutral $30
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20Downgrade UBS Buy → Neutral $35
Nov-05-19Initiated Wolfe Research Outperform
Nov-04-19Initiated UBS Buy $21
Nov-04-19Initiated SVB Leerink Outperform
Nov-04-19Initiated JP Morgan Overweight $23
Nov-04-19Initiated Canaccord Genuity Buy $22
Nov-04-19Initiated BofA/Merrill Buy $21
Nov-04-19Initiated Berenberg Buy $25
Apr-17-21 08:23AM  
Apr-16-21 04:07PM  
01:53PM  
11:07AM  
09:23AM  
08:39AM  
07:17AM  
Apr-15-21 03:41PM  
03:13PM  
02:04PM  
07:35AM  
04:21AM  
03:49AM  
Apr-14-21 05:36PM  
02:11PM  
01:43PM  
01:15PM  
11:02AM  
09:34AM  
08:46AM  
08:21AM  
08:17AM  
05:35AM  
Apr-13-21 02:09PM  
11:00AM  
10:51AM  
10:45AM  
10:42AM  
10:28AM  
10:06AM  
10:04AM  
09:28AM  
05:51AM  
05:35AM  
Apr-12-21 02:43PM  
01:51PM  
09:30AM  
07:05AM  
05:35AM  
Apr-11-21 12:13PM  
12:07PM  
Apr-10-21 05:49AM  
Apr-09-21 04:20PM  
02:13PM  
01:39PM  
01:22PM  
10:56AM  
10:25AM  
09:55AM  
09:25AM  
Apr-08-21 08:00PM  
05:00PM  
03:23PM  
01:23PM  
06:04AM  
Apr-07-21 01:26PM  
12:28PM  
11:01AM  
Apr-06-21 01:29PM  
12:00PM  
11:09AM  
06:57AM  
05:52AM  
Apr-05-21 02:06PM  
01:54PM  
11:25AM  
08:16AM  
05:37AM  
02:05AM  
Apr-04-21 10:09AM  
Apr-03-21 10:48AM  
03:00AM  
Apr-02-21 08:00PM  
01:46PM  
08:45AM  
08:05AM  
07:03AM  
06:17AM  
02:48AM  
Apr-01-21 08:00PM  
05:00PM  
04:18PM  
04:15PM  
04:12PM  
01:46PM  
12:48PM  
10:35AM  
09:42AM  
08:25AM  
07:33AM  
07:27AM  
07:07AM  
07:02AM  
06:50AM  
06:45AM  
06:45AM  
06:09AM  
05:23AM  
04:19AM  
Mar-31-21 08:30PM  
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.